Guidelines for Diagnosis and Management of Secondary (or Tertiary) Adrenal Insufficiency
1. Pathophysiology and Risk Factors
- Exogenous glucocorticoids, especially dexamethasone, suppress endogenous cortisol production and can lead to prolonged hypothalamic‑pituitary‑adrenal (HPA) axis suppression, particularly with higher doses or long‑term use. 1
- A daily dose of prednisone ≥ 20 mg (or equivalent) for ≥ 3 weeks is sufficient to cause HPA axis suppression. 4
- Inhaled, topical, intra‑articular, and intranasal corticosteroids are also capable of suppressing the HPA axis. 5
- Dexamethasone’s longer plasma elimination half‑life compared with hydrocortisone contributes to more persistent HPA axis suppression. 1
2. Diagnostic Considerations
2.1 Interpretation of the Dexamethasone Suppression Test
- The dexamethasone suppression test is primarily a tool for diagnosing Cushing’s syndrome; a markedly suppressed cortisol after dexamethasone indicates excessive HPA axis suppression rather than hypercortisolism. 2
2.2 Limitations of Morning Cortisol Measurements
- Morning serum cortisol measured while the patient is still receiving corticosteroids is unreliable because most assays detect both endogenous cortisol and the administered steroid, leading to false‑positive “adrenal insufficiency” results. 4
2.3 Thresholds for Suspecting Secondary Adrenal Insufficiency
- Morning cortisol 5–10 µg/dL (140–275 nmol/L) together with a low or inappropriately normal ACTH level is indicative of secondary adrenal insufficiency. 1
3. Confirmatory Testing
- Cosyntropin (ACTH) stimulation test – administer 0.25 mg (250 µg) cosyntropin intravenously or intramuscularly, then measure cortisol at baseline, 30 min, and 60 min. 4
- A peak cortisol < 500 nmol/L (< 18 µg/dL) confirms adrenal insufficiency. Evidence level: high (systematic review). 6
- A peak cortisol > 550 nmol/L (> 18–20 µg/dL) effectively excludes adrenal insufficiency. 4
4. Timing of Laboratory Evaluation
- Diagnostic testing should be deferred until all exogenous glucocorticoids have been discontinued with an appropriate wash‑out period (hydrocortisone ≥ 24 h; longer for prednisone, dexamethasone, etc.). 4
- For patients with chronic steroid‑induced secondary adrenal insufficiency, HPA‑axis recovery testing should be postponed for at least 3 months after switching to maintenance hydrocortisone. 4
5. Treatment Strategies
5.1 Chronic Glucocorticoid Replacement
- Standard regimen: hydrocortisone 15–25 mg daily in divided doses (e.g., 10 mg upon waking, 5 mg at midday, 2.5–5 mg late afternoon). Evidence level: moderate. 4
- Alternative options: cortisone acetate 25–37.5 mg daily or prednisone 3–5 mg daily. 4
- Mineralocorticoid replacement (fludrocortisone) is not required in secondary adrenal insufficiency because the renin‑angiotensin‑aldosterone system remains functional. 5
5.2 Emergency Preparedness
- Provide every patient with an emergency injectable hydrocortisone 100 mg intramuscular kit and training for self‑administration. 4
- Instruct patients to double or triple their usual oral hydrocortisone dose during mild to moderate illness, fever, or physical stress. 4
- Recommend wearing a medical alert bracelet or necklace indicating adrenal insufficiency. 4
- Stress‑dose guidance:
- Minor stress – double usual dose for 1–2 days.
- Moderate stress – hydrocortisone 50–75 mg orally per day.
- Major stress/surgery – hydrocortisone 100–150 mg intravenously per day. 4
5.3 Management of Recent Steroid Taper
- For patients recently tapered off glucocorticoids, consider empiric glucocorticoid replacement and schedule HPA‑axis retesting at 3 months rather than immediate diagnostic testing. 4
- Referral to endocrinology is advised for individualized weaning protocols and monitoring of axis recovery. 4
6. Critical Pitfalls
- Do not delay treatment of suspected adrenal crisis; administer IV hydrocortisone 100 mg immediately plus rapid isotonic saline infusion. Evidence level: high. 5
- Avoid performing diagnostic testing while the patient remains on any corticosteroid, as this will produce misleading results. 4
- Electrolyte patterns are not definitive: hyponatremia occurs in ~90 % of adrenal insufficiency cases, whereas hyperkalemia is present in only ~50 % and is typically absent in secondary disease. 4
- Lifelong glucocorticoid replacement must not be discontinued in patients with confirmed primary or secondary adrenal insufficiency of non‑iatrogenic origin. 4
7. Recognition of Acute Adrenal Crisis
- Immediate IV hydrocortisone 100 mg is mandated in patients presenting with any of the following: unexplained hypotension refractory to vasopressors, severe weakness or altered mental status, profuse vomiting/diarrhea with dehydration, or sudden collapse with gastrointestinal symptoms. 4
- Untreated adrenal crisis carries a high mortality rate; treatment must precede any confirmatory testing. 4